病毒学失败是指ART治疗未能将HIV RNA水平保持在200拷贝/mL以下。 当前的HIV RNA检测中,经常会出现20至200拷贝/mL之间的间歇性病毒反弹(称为“blip”),这种现象比较常见,不应因此更换治疗方案,但需要关注患者的ART依从性,并检查是否有干扰药物或...
病毒学失败是指ART治疗未能将HIV RNA水平保持在200拷贝/mL以下。 当前的HIV RNA检测中,经常会出现20至200拷贝/mL之间的间歇性病毒反弹(称为“blip”),这种现象比较常见,不应因此更换治疗方案,但需要关注患者的ART依从性,并检查是否有干扰药物或补充剂的使用,例如含多价阳离子的物质(钙、镁、铁或锌等),这些物质...
7. Trottier B, et al. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-country cohort study.HIV Glasgow 2022, P067. 往期推荐 ID Week前沿丨突破极限!
[9] Orkin C, DeJesus E, Sax P E, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials...
7. Trottier B, et al. Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the treatment of people living with HIV: 24-month (24M) analyses by age, race, sex, adherence and late presentation in a multi-...
[9] Orkin C, DeJesus E, Sax P E, et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials...
在治疗和未治疗人群中,可能出现三种不同的HIV耐药类型,分别为获得性耐药(ADR)、治疗前耐药(PDR)、传播性耐药(TDR)。 顾名思义,ADR是指个体在接受ART治疗时,由于HIV复制而发生基因突变,进而产生的耐药现象;PDR是指从未接触抗病毒治疗的个体在开始一线ART前,或既往已接受ART的患者重新开始一线ART前,体内就已检测到...
et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials[J]. The Lancet HIV, 2020, 7(6): ...
likely you'll give HIV to anyone else as long as you take them as prescribed by your doctor. If you're at risk of getting HIV, you may start treatment to protect yourself from the virus in advance. Ask your doctor about your treatment options, which they'd recommend for you, and why...
Adherence to antiretroviral treatment (ART) of HIV-infected persons with or without injection drug use (IDU) or in a drug addiction treatment program: the Swiss HIV cohort studyHuber MD, MiloLedergerber, BrunoFurrer, HansjakobElzi, Luigia